SAN ANTONIO--(BUSINESS WIRE)--Kinetic Concepts, Inc. (NYSE:KCI), a global medical technology company with leadership positions in advanced wound care and therapeutic surfaces, today announced that it has entered into an exclusive worldwide license with NovaBay Pharmaceuticals, Inc. for its proprietary NeutroPhase topical solution technology in the field of wound healing. NeutroPhase is a stable, rapid-acting solution containing hypochlorous acid, which is known to kill a broad range of bacteria in seconds. KCI intends to develop and commercialize NeutroPhase for the cleansing of wounds, and for use in combination with KCI’s proprietary V.A.C.® instillation therapies.
